Skip to main content
Clinical Trials/ITMCTR2100004503
ITMCTR2100004503
Recruiting
Phase 1

A multicenter randomized controlled clinical study of Qishao Tianxin prescription in the treatment of early urinary incontinence after radical prostatectomy for prostate cancer.

Beijing Chaoyang Hospital, Capital Medical University0 sitesTBD

Overview

Phase
Phase 1
Intervention
Not specified
Conditions
rinary incontinence
Sponsor
Beijing Chaoyang Hospital, Capital Medical University
Status
Recruiting
Last Updated
3 years ago

Overview

Brief Summary

No summary available.

Registry
who.int
Start Date
TBD
End Date
TBD
Last Updated
3 years ago
Study Type
Interventional study
Sex
All

Investigators

Sponsor
Beijing Chaoyang Hospital, Capital Medical University

Eligibility Criteria

Inclusion Criteria

  • From January 2020 to June 2023, patients aged 55\-75 who are prepared for radical resection of prostate cancer are mainly middle\-to\-high\-risk prostate cancer patients:
  • (1\) PSA \>\= 10; Or 4\<\=PSA\<\=10 and F/T \< 0\.16;
  • (2\) TNM stage of prostate cancer \>\= T2 stage;
  • (3\) Gleason score \>\= 7 points;Or the puncture Gleason score of both lobes \>\= 6 points at the same time; informed and agreed to participate in the clinical trial; able to cooperate with the treatment and complete the follow\-up.

Exclusion Criteria

  • Patients with heart, brain and lung diseases or liver and renal insufficiency.

Outcomes

Primary Outcomes

Not specified

Similar Trials